In the ®rst trimester of pregnancy the biochemical markers free b-hCG and pregnancy associated plasma protein-A (PAPP-A) are used for the prenatal screening of trisomy 21, either alone or in combination with nuchal translucency (NT) thickness. In this study, I have analysed the distribution of these
First-trimester screening with free β-hCG, PAPP-A, and nuchal translucency in pregnancies conceived by in vitro fertilization
✍ Scribed by Sriram C. Perni; Mladen Predanic; Alexander Friedman; Claudel Jean-Pierre; Robin B. Kalish; Stephen T. Chasen
- Book ID
- 113428307
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 77 KB
- Volume
- 191
- Category
- Article
- ISSN
- 1097-6868
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
In a population of 1467 women attending the 'G. Gaslini' Institute for antenatal care, we evaluated first-trimester risk screening for Down syndrome using the 'combined test' based on ultrasound measurement of nuchal translucency (NT), maternal serum pregnancy-associated plasma protein A (PAPP-A) an
We have examined maternal urine concentrations of beta core, free beta human chorionic gonadotrophin (hCG), and total oestriol in 373 control pregnancies and 43 pregnancies affected by aneuploidy (including 22 cases of Down's syndrome) in an attempt to see if any of the analytes have a value in Down